Cargando…

Movement Disorders and Dementia in a Woman With Chronic Aluminium Toxicity: Video-MRI Imaging

BACKGROUND: Aluminium encephalopathy results from exposure to aluminium from occupational, recreational, and environmental sources. Movement disorders, cerebellar ataxia, pyramidal tract signs, dementia, microcytic anemia and bone disease are typical manifestations. CASE REPORT: A 55-year-old woman...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes, Antonio Jose, Ramcharan, Kanterpersad, Giddings, Stanley Lawrence, Ramesar, Amrit, Arias, Edmundo Rivero, Rampersad, Fidel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863844/
https://www.ncbi.nlm.nih.gov/pubmed/33598364
http://dx.doi.org/10.5334/tohm.588
Descripción
Sumario:BACKGROUND: Aluminium encephalopathy results from exposure to aluminium from occupational, recreational, and environmental sources. Movement disorders, cerebellar ataxia, pyramidal tract signs, dementia, microcytic anemia and bone disease are typical manifestations. CASE REPORT: A 55-year-old woman had clinical manifestations, persistent hyperaluminemia without magnetic resonance imaging (MRI) scan changes of toxic encephalopathy following a prolonged exposure to marine grade paints containing 30% aluminium. Chelation therapy with ethylenediaminetetraacetic acid (EDTA) demonstrated decreased levels of aluminemia and significant neurological improvement over time. DISCUSSION: This diagnosis should be entertained in patients with movement disorders, cerebellar ataxia, pyramidal signs, and dementia of unknown etiology. HIGHLIGHTS: Aluminium encephalopathy (AE) is a neurological syndrome caused by aluminium neurotoxicity. Manifestations include cognitive impairment, motor dysfunction, microcytic anemia and bone disease. This case illustrates AE with hyperaluminemia associated with chronic exposure to industrial paints and clinical and biochemical reversibility after chelation therapy with ethylenediaminetetraacetic acid. Movement disorders are highlighted.